Assessment of the Pharmacokinetics and Safety of ANT3310 Combined With Meropenem in Renally Impaired Subjects

Main Inclusion Criteria: * Participant must be 18 to 80 years of age (both inclusive) at the time of signing the informed consent. * BMI within the range of 18.0 to 36.0 kg/m2 (both inclusive) with a body weight ≥ 50 kg. * Contraceptive use by women or men should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * Capable of giving signed informed consent in compliance with the requirements and restrictions listed in the ICF and in the protocol. * Ability to cooperate with the investigator and to comply with the requirements of the trial. * Sufficient venous access for i.v. infusion and PK samplings. * For participants with renal function impairment: Individualized eGFR \<90 mL/min at screening, estimated according to the individualized CKD-EPI equation and stable renal function. * For participants with ESRD requiring dialysis: Chronic intermittent hemodialysis for ≥3 months prior to dosing. * For participants with normal renal function: Individualized eGFR ≥90 mL/min at screening, estimated based on serum creatinine measured within 10 days prior to Day -1 according to the CKD-EPI equation. Main Exclusion Criteria: * Febrile illness within 1 week before admission to the study center. * Known hypersensitivity to meropenem and or ANT3310 or any of the excipients of the infusion solution. * Known severe allergies, non-allergic drug reactions, or multiple drug allergies requiring intranasal or systemic corticosteroids during any time of the year or history of any anaphylactic reaction. * Medical disorder, condition, or history of such that would - in the opinion of the investigator - compromise the participant's ability to participate in this study. * History of epilepsy (or known seizure disorder), brain lesions or other significant neurological disorders. * Known history of clinically significant hypersensitivity or urticaria, or severe allergic reaction to β-lactam antibiotics (e.g., penicillin, cephalosporin, carbapenem, or monobactam). * History of Gilbert syndrome. * History of any severe antibiotic-associated superinfections like Clostridium difficile colitis and/or frequent fungal vaginal infections. * Therapies (e.g., physiotherapy, acupuncture, etc.) within 1 week before study drug administration. * Positive results for HBsAg, anti-HCV, HIV antibodies (anti-HIV 1+2). * For participants with impaired renal function: Acute renal failure or active renal infections, Clinically significant impaired hepatic function, Severe infection or any clinically significant illness within 4 weeks before dosing, Impairment of any other major organ system other than the kidney except underlying disease, Diagnosed malignancy during the past 5 years except completely resected basal cell cancer of the skin, Any kidney transplant during the last 10 years, any other organ transplant during the past 5 years.